ArticleChemistry & biodiversity2026
Antiurolithiatic Potential of a Series of Phthalimide Derivatives on Calcium Oxalate Crystals.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antiurolithiatic Potential of a Series of Phthalimide Derivatives on Calcium Oxalate Crystals.Chemistry & biodiversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Urolithiasis, primarily caused by calcium oxalate crystals, represents a major health concern due to high recurrence rates and limitations of current treatments in dissolving existing stones. This study investigated the antiurolithiatic potential of 15 phthalimide derivatives against calcium oxalate monohydrate (COM) and dihydrate (COD) crystals. The compounds were synthesized via condensation of phthalic anhydride with nitrogenous bases and evaluated using urine samples from rats with sodium oxalate-induced crystallization. All derivatives reduced COM crystal formation at one or more concentrations, though only LD-F 03 inhibited COD crystals. Notably, LD-F 10 decreased COM by 89%, whereas LD-F 11 achieved 92% COM inhibition. These results demonstrate the structural versatility of phthalimides and the need to optimize molecular design for selective activity. Overall, phthalimide derivatives show promising antiurolithiatic effects, warranting further studies on pharmacokinetics, safety, and potential combination with current therapies to reduce recurrence and surgical interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.